Phase II clinical trial of vaccine candidate Soberana Plus to include 450 COVID 19 convalescents
The Phase II clinical trials of Soberana Plus in convalescents of COVID 19 will include 450 people and will broaden the inclusion criteria compared to Phase I, informed today an expert from the Finlay Vaccine Institute (IFV), the entity that developed this vaccine candidate against COVID-19.
- Written by ACN
- Category: Health
- Hits: 1076